Antibody Drug Conjugates Contract Market
Antibody Drug Conjugates Contract Market by Condition Type (Myeloma, Lymphoma, Breast Cancer, Other Condition Types), Application Type (Cleavable Linker, Non-cleavable Linker), and By Region - Global Research 2022 to 2032
Antibody Drug Conjugates Contract Market Outlook
Newly-released Antibody Drug Conjugates Contract Market industry analysis report by Fact.MR shows that global sales of the Antibody Drug Conjugates Contract Market in 2021 were held at US$ 8.1 Bn. With a CAGR of 15.5 %, the projected market growth during the period 2022-2032 is expected to be slightly higher than the historical growth which stood at 12.7%.
The Antibody Drug Conjugates Contract Market is accounted to give an absolute dollar opportunity growth of nearly US$ 29.7 Bn during 2022 – 2032. Myeloma is expected to be the highest revenue-generating condition type.
Interested to Procure The Data
Key Points Covered in Antibody Drug Conjugates Contract Market:
- Market Estimates and Forecasts (2015-2032)
- Key Drivers and Restraints Shaping Market Growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Market Share Analysis
- COVID-19 Impact on Antibody Drug Conjugates Contract Market and How to Navigate
- Recommendation on Key Winning Strategies
Revenue of Antibody Drug Conjugates Contract Market from 2015 to 2021 Compared to Demand Outlook for 2022 to 2032
As per the Antibody Drug Conjugates Contract Market industry research by Fact.MR - market research and competitive intelligence provider, historically, from 2015 to 2021, the market value of the Antibody Drug Conjugates Contract Market industry increased at around 12.7% CAGR, wherein, countries such as the U.S., China, Japan, South Korea, and the UK held a significant share in the global market.
The market for Antibody Drug Conjugates Contract is expected to grow at an immense rate and show some great results in the upcoming years. The global production of antibody-drug conjugates contracts, vaccines, and other pharmaceuticals is expected to increase as a result of the increased demand for effective COVID-19 treatments.
The Antibody Drug Conjugates Contract Market reached a valuation of US$ 8.1 Bn in 2021 and is expected to cross US$ 9.2 Bn mark by the end of the 2022.
- Top condition type Myeloma is expected to grow with a huge CAGR of 17% during the forecasted period of 2022 to 2032
- From the top application type perspective, Cleavable Linker has shown the CAGR of 12.6% in the historical data and is expected to grow at the rate of 17.2% in the next 10 years.
- From the North America region, the United States market size by the end of forecast period is anticipated to be around US$ 7.3 Bn with an absolute dollar growth of US$ 5.3 Bn.
An Adaptive Approach to Modern-day Research Needs
What is the current overview for the Antibody Drug Conjugates Contract Market?
Antibody-drug conjugate contract is complex powerful biologics that have the potential to treat a wide range of ailments, including cancer. The capacity of these therapies to successfully target disease-associated cells while limiting off-target damage is credited with their clinical potential.
According to the ADC Review, about 70% of ADC projects are outsourced to contract development and manufacturing organisations (CDMOs), and this trend is projected to continue with the pipelines' continuing expansion. As more commercial goods reach the market, CDMOs who understand how to conduct late-stage studies to support the filing strategy is in high demand.
CMOS are setting up systems to address the difficult supply chains and investing in facilities and processes to ensure security, quality, and efficiency in commercial-scale ADC manufacture. As a result of the planned growth in ADC demand, the contract manufacturing market for ADCs is expected to grow significantly in the future years.
What are the strong footholds for the Antibody Drug Conjugates Contract Market?
The Antibody Drug Conjugates Contract Market is predicted to grow significantly throughout the forecast period as a result of subcontracting services and operations to contract manufacturing organizations, increased demand for biologic treatments, and rising cancer occurrences.
With time and research, scientists have enhanced the design and development procedure for these medicines. As a result, four new ADCs will be approved in 2019 and 2020. The US Food and Drug Administration has approved 12 ADCs so far, with another 100 in the works.
Avail customized purchase options for your needs
What are the current restraining factors for the Antibody Drug Conjugates Contract market?
The growing complexity of the biologic business makes most drugs today made by pharmaceutical companies. This, in turn, has negatively impacted the market for contract manufacturing of antibody drug conjugates.
ADCs are a unique niche in the pharmaceutical industry, with numerous manufacturers executing almost all of the steps, resulting in a high risk of bureaucratic complications. Additionally, since there is about 70 failed clinical trials for ADCs and just a few commercialized products, there is a need to streamline the supply chain to increase productivity.
Which Region is projected to offer the Largest Opportunity for Antibody Drug Conjugates Contract Market?
The Asia Pacific led the antibody-drug conjugates contract manufacturing market with a 46.4 %revenue share in 2020. The Asia Pacific accounts for 48% of all new cancer cases worldwide. Out of all the cases, China holds nearly half of the sufferers.
The market for APAC antibody-drug conjugates contract is developing due to the rising frequency of cancer and the growing geriatric population. According to Globocan Data 2020, 52 % of cancer patients are 65 or older, and by 2040, this number is expected to quadruple. The most frequent cancer in China is lung cancer, which is followed by stomach, liver, colon, rectum, and breast cancers.
At what area does the Antibody Drug Conjugates Contract get an edge in treatment?
Several cancer drugs cause serious side effects and limit their dose and efficacy, reducing the safety and effectiveness of the treatment. These issues are largely resolved through the use of antibody-drug conjugates.
How is the elderly population is going to be a contributor to the global Antibody Drug Conjugates Contract Market over some regions?
The elderly are said to have a higher cancer rate than the younger population. According to a 2019 article on the aging of the global population, by 2050, the number of people aged 65 and up will reach 17% of the global population.
According to the World Health Organization (WHO), 82 % of older people would reside in Organization for Economic Cooperation and Development (OECD) countries by 2050. The aging of the population will have a significant impact on healthcare systems.
How can Antibody Drug Conjugates Contract assist oncology and hematology?
In the fields of oncology and hematology, antibody-drug conjugates contracts are also used. Every year, over 8.5 million people die from cancer around the world. Doctors all across the world are working to develop cutting-edge medications and therapies that will cure cancer cells without harming healthy cells.
There has been a rise in cancer treatment in hospitals due to the increased occurrence of cancer-related to genetic predispositions, unhealthy lifestyles, and occupational dangers. Antibody-drug conjugates have helped several aggressive tumors like leukemia, hepatocellular carcinoma, and other hematological disorders.
Which Country represents the strongest revenue potential in the upcoming years for Antibody Drug Conjugates Contract Market Revenue?
The US government will be driving the market of U.S. medicinal products through ADC contracts. The projected CAGR for the period from 2015 to 2021 is 13.1%, and that from 2021 to 2032 is 13.7%. By 2032, the U.S. leads the market with a projected CAGR of US$ 7.3 Bn.
The growing instances of cancer in the United States, in addition to looking for coping techniques, is raising the interest in ADCs. According to the Centers for Disease Control and Prevention (CDC), 1,708,921 new cancer cases were reported in the US in 2018, with a total of 599,265 deaths. As of May 2021, the Food and Drug Administration (FDA) has approved ten radiopharmaceuticals for treating breast cancer, bladder cancer, multiple myeloma, acute leukemia, and lymphoma.
Why Myeloma is Gaining the Utmost Traction when compared with other Condition Types of Antibody Drug Conjugates Contract?
The Myeloma segment is the top condition type segment which grew with a CAGR of 13.2% during 2015-2021 and is anticipated to bounce and grow with a CAGR of 17% in the forecasted period of 2022-2032. This is partly because antibody-drug conjugates contract is a new type of immunotherapy that is now being investigated and evaluated in the treatment of myeloma.
The target site for the monoclonal antibody is the main aggressive component of the monoclonal antibody. As a result, this kind of medication has a very variable effect on damaged cells. As a result, this therapeutic modality is more effective in treating patients suffering from multiple myeloma because it has a rapid onset and broad applicability.
How is Cleavable Linker is more promising application type segment?
The most essential aspect affecting the section's expansion is the compensations that cleavable linkers receive in various situations to provide medicine to the object cell. The market segment for cleavable linkers grew with a CAGR of 12.6% during the historical period of 2015-2021 is expected to grow with a CAGR of 17.2% during the forecasted period of 2022-2032.
Cleavable linkers are the most commonly available kind of ADC linker. The most significant benefit of cleavable linkers is the fact that they are cleaved in response to extracellular and intracellular environments by environmental and lysosomal enzymes.
According to a paper published in April 2019 called "Analysis of key factors related to ADCs structural design," cleavable linkers were used in more than two-thirds of ADCs currently in use in clinical trials.
What was the impact of COVID-19 on the Antibody Drug Conjugates Contract Market?
With tragic loss of life due to covid-19, an optimistic and conscious strategy has transpired concerning monoclonal antibody development, not solely for those antibodies which were thought best prior to a year, but also for other antibody-drug conjugate (ADCs) that have come to be regarded as potential covid-19 treatments.
The epidemic has sparked a strong and swift response from government and industry experts working on treatments and vaccines. The global production of antibody-drug conjugates, vaccines, and other pharmaceuticals is expected to increase as a result of the increased demand for effective COVID-19 treatments.
The contract manufacturing industry for antibody drug conjugates is very competitive, with numerous prominent companies. Pantheon, Corden Pharma, Abbvie Inc, Novasep, Merck Lonza group, Cambrex Corporation, Recipharm, Thermo Fisher Scientific, Inc, and Sterling Pharma Solutions are some of the market leaders.
Companies are making significant efforts and capital investments to increase their skills and, as a result, enhance their respective service lineups in order to acquire a competitive advantage. Some companies have built new facilities dedicated to the production of highly powerful chemicals. Various agreements between medication inventors and ADC makers have also been observed in the field.
Some of the recent developments of Antibody Drug Conjugates Contract Market providers are as follows:
- In January 2022, Recipharm announced the purchase of GenIbet to expand its biologics platform.
- In August 2021, Recipharm announced that it has opened a new laboratory to boost its analytical services.
- In July 2021, Lonza Group has extended its relationship with a large biopharmaceutical sector client for the supply of an antibody-drug conjugate against hard-to-treat malignancies.
- In September 2020, Merck announced a EUR 59 million expansion of its ADC manufacturing capabilities at its Wisconsin site. This investment is likely to enable the large-scale production of increasingly effective chemicals for cancer therapy.
Similarly, recent developments related to companies offering Antibody Drug Conjugates Contract Market have been tracked by the team at Fact.MR, which are available in the full report.
Antibody Drug Conjugates Contract Report Scope
Historical Data Available for
US$ Bn for Value
Key Regions Covered
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
Available upon Request
Market Segments Covered in Antibody Drug Conjugates Contract Market Industry Analysis
By Condition Type
- Breast Cancer
- Other Condition Types
- Cleavable Linker
- Non-cleavable Linker
- North America
- Latin America
- FAQs -
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
The drug discovery technologies market to reach US$ 81.5 bn as worldwide demand for drug discovery t...
Ocular Implants Market is expected to reach a value of US$ 19.47 Bn by 2032. Glaucoma implants segme...
Finasteride Market - Global Industry Analysis 2016 - 2020 and Opportunity Assessment 2021 - 2031...